1-6 of 6
Tara L. Cronin
Close
Sort by
Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9010–9012.
https://doi.org/10.1182/blood-2022-164707
Published: 2022
Journal Articles

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Hassan Awada, Mina Abdelmalek, Tara L. Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark G. Faber, Arya Roy, Ashish Gupta, Matthew Gravina, Sheeba Ba Aqeel, Alankrita Taneja, Pamela J. Sung, Steven D. Green, Amanda Przespolewski, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 135–136.
https://doi.org/10.1182/blood-2022-168482
Published: 2022
Journal Articles

Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis

Manu Pandey, MBBS, Mahesh Swaminathan, MBBS, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amanda Przespolewski, DO, Swapna Thota, MD, Jeffrey Baron, PharmD, Tara L. Cronin, BA, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3866.
https://doi.org/10.1182/blood-2019-132123
Published: 2019
Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1371.
https://doi.org/10.1182/blood-2019-130427
Published: 2019
Journal Articles

Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia

Amanda Przespolewski, DO, Craig W. Freyer, PharmD, Wenyan Ji, MA, Tara L. Cronin, BA, Swapna Thota, MD, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Amro Elshoury, MBBChir, Jeffrey Baron, PharmD, Mark Walsh, PharmD, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1361.
https://doi.org/10.1182/blood-2019-130582
Published: 2019
Journal Articles

Mitophagy Plays a Key Role in the Anti-Leukemic Activity of Autophagy Inhibitors Under Hypoxia in Acute Myeloid Leukemia

Hannah R.S. Fay, BS, Kaitlyn M. Dykstra, PhD, Matthew Johnson, Tara L. Cronin, BA, Linda Lutgen-Dunckley, Brandon L. Martens, BS, Joseph R. Moberg, BS, Monica L. Guzman, PhD, Eunice S. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1278.
https://doi.org/10.1182/blood-2019-127024
Published: 2019